around 10% of the population are affected by mild cognitive decline. The burden of cognitive decline can be quantified at the cost to the individuals themselves and to society. A policy based on these figures can potentially generate significant revenue.
The signs of cognitive decline in the present study included a decrease in verbal ability. However, these deficits were present in the very early stages of the disease, suggesting that cognitive deterioration does not require a long period of subclinical disease activity before it becomes apparent.
Although it appears to be possible to cure the cognitive decline that is characteristic of Alzheimer's disease, it is not generally possible to cure the decline that can often be seen in people with MCI.
In the elderly, medication is not the most common treatment for cognitive decline. Cognitive and behavioural therapies are commonly used and have been well received, especially when used in conjunction with medication. However, there has been only a relatively small amount of high-quality research on cognitive treatments in the elderly.
The two common theories for the origins of cognitive decline are age-related brain changes and Alzheimer's disease-like dementias. More research regarding the impact of other medical conditions, medications, and health habits and environmental factors on cognition is needed.\n
This article offers an in-depth review of the causes and effects of cognitive decline, while also providing a theoretical perspective on how cognition can be conceptualized and studied. Specifically, a new concept proposed in this article--cognitive reserve--relates to the degree of longevity an individual's coping capability can afford before manifesting cognitive decline. The concept is applied to the geriatric population and clinical populations suffering from cognitive decline. Copyright © 2015 John Wiley & Sons, Ltd.
There were more common side effects from brainstrong-gsr therapy than other therapies. However, the treatment of brainstrong-gsr was well tolerated. The most common side effects were fatigue, mood alteration, and headache. The side effects of brainstrong-gsr were mostly moderate and mild and lasted for a short period.
Brainstrong-gsr is typically used in combination with some other treatment, especially for people with multiple sclerosis. While data from this review are limited by the inclusion criteria of multiple sclerosis, it is suggested that these treatments should be tested in patients with multiple sclerosis with and without AD. There is more high-quality, evidence-based validation of brainstrong-gsr as a monotherapy for AD, and a greater understanding of how brainstrong-gsr could be used with a different treatment plan for Alzheimer's disease, e.g. for mild cognitive impairment.
There is evidence that cognitive deficits may have been a risk factor for Alzheimer's disease. Findings from clinical trials of drugs aimed at preventing Alzheimer's disease as well as neuroprotection are beginning to show positive effects. Given the rapid aging in our society, researchers are focusing on medications and lifestyle adjustments that can have a positive impact on cognitive decline. Given the growing urgency of the issue, there is a need for more longitudinal information about cognitive decline and approaches to reduce its risk.
Results from a recent clinical trial show that people with epilepsy may be able to benefit from cognitive rehabilitation treatment, especially on executive functions. However, there is a need for further research on the type of rehabilitation that can be beneficial to the people in this group and the benefits in comparison to the control group.
Recent findings provides proof of concept that Brainstrong-Gsr is more effective than the placebo on cognitive, psychological, and quality of life. Brainstrong-Gsr should be considered for future clinical trials for the treatment of mild cognitive impairment and other cognitive disorders due to its superior effectiveness compared with a placebo and a positive safety profile.
Results from a recent paper of this pilot study suggest that brainstrong may serve as a useful tool as a quality-of-life intervention tool for cognitively impaired individuals, particularly for memory issues. Future work will have to be done in larger randomized studies of patients receiving cognitive enhancement intervention.